Trust Company of the Ozarks’s AstraZeneca AZN Stock Holding History

Trust Company of the Ozarks’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-9,766	Closed	-$634K	–	168
2014 Q1	$634K	Hold	9,766	–	–	0.18%	95
2013 Q4	$580K	Hold	9,766	–	–	0.17%	97
2013 Q3	$507K	Sell	9,766 -125	-1%	-$6.28K	0.16%	99
2013 Q2	$467K	Buy	+9,891	New	+$504K	0.16%	102

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trust Company of the Ozarks's AZN Position: Q2 2014 in Review

Trust Company of the Ozarks sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 9,766 shares — an estimated $634K sold.

Trust Company of the Ozarks first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $634K in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Trust Company of the Ozarks reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Trust Company of the Ozarks sold 9,766 AstraZeneca shares in Q2 2014, an estimated $634K.
Trust Company of the Ozarks first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
Trust Company of the Ozarks's AstraZeneca position peaked at $634K in Q1 2014.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Trust Company of the Ozarks's 13F filing for Q2 2014, filed 12 Aug 2014.